Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Segment Information - Summary of Making Decisions Regarding the Allocation of Resources and to Assess Performance (Details)

v3.22.1
Segment Information - Summary of Making Decisions Regarding the Allocation of Resources and to Assess Performance (Details) - EUR (€)
€ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Segment Information [Line Items]      
Revenues € 843,920 € 662,037 € 536,539
Cost of sales 578,515 467,861 398,518
Gross Profit 265,405 194,176 138,021
Other operating income 9,386 5,230 8,737
Selling and Marketing expenses 20,448 20,044 26,144
Research and Development expenses 29,616 17,390 7,826
General and Administrative expenses 62,502 58,863 50,568
Operating Profit 162,225 103,109 62,220
Total assets 1,418,842 967,979  
Total liabilities 577,183 657,839  
External Customers      
Segment Information [Line Items]      
Revenues 843,920 662,037 536,539
Adjustments, Eliminations and Unallocated Items      
Segment Information [Line Items]      
Revenues (70,113) (57,423) (46,506)
Cost of sales (63,393) (51,882) (39,312)
Gross Profit (6,720) (5,541) (7,194)
Other operating income   7 0
Selling and Marketing expenses 9,516 7,440 9,255
Research and Development expenses 1,886 2,254 835
General and Administrative expenses (8,392) 899 (756)
Operating Profit (9,730) (16,127) (16,528)
Total assets 279,342 2,396  
Total liabilities 77,603 217,890  
Adjustments, Eliminations and Unallocated Items | Inter-Segment      
Segment Information [Line Items]      
Revenues (70,113) (57,423) (46,506)
Biopharmaceutical and Diagnostic Solutions | Operating Segments      
Segment Information [Line Items]      
Revenues 695,172 566,027 455,922
Cost of sales 465,304 398,411 333,539
Gross Profit 229,868 167,616 122,383
Other operating income 9,386 5,193 8,737
Selling and Marketing expenses 7,736 9,762 13,776
Research and Development expenses 23,467 12,080 5,442
General and Administrative expenses 58,996 48,324 43,167
Operating Profit 149,055 102,643 68,735
Total assets 885,733 776,832  
Total liabilities 335,919 330,624  
Biopharmaceutical and Diagnostic Solutions | Operating Segments | External Customers      
Segment Information [Line Items]      
Revenues 694,038 564,931 455,041
Biopharmaceutical and Diagnostic Solutions | Operating Segments | Inter-Segment      
Segment Information [Line Items]      
Revenues 1,134 1,096 881
Engineering | Operating Segments      
Segment Information [Line Items]      
Revenues 218,861 153,433 127,123
Cost of sales 176,604 121,332 104,291
Gross Profit 42,257 32,101 22,832
Other operating income   31 0
Selling and Marketing expenses 3,196 2,842 3,113
Research and Development expenses 4,263 3,056 1,549
General and Administrative expenses 11,898 9,641 8,157
Operating Profit 22,900 16,593 10,013
Total assets 253,767 188,751  
Total liabilities 163,661 109,325  
Engineering | Operating Segments | External Customers      
Segment Information [Line Items]      
Revenues 149,882 97,106 81,498
Engineering | Operating Segments | Inter-Segment      
Segment Information [Line Items]      
Revenues 68,979 56,327 45,625
Total Segments | Operating Segments      
Segment Information [Line Items]      
Revenues 914,033 719,460 583,045
Cost of sales 641,908 519,743 437,830
Gross Profit 272,125 199,717 145,215
Other operating income 9,386 5,224 8,737
Selling and Marketing expenses 10,932 12,604 16,889
Research and Development expenses 27,730 15,136 6,991
General and Administrative expenses 70,894 57,965 51,324
Operating Profit 171,955 119,236 78,748
Total assets 1,139,500 965,583  
Total liabilities 499,580 439,949  
Total Segments | Operating Segments | External Customers      
Segment Information [Line Items]      
Revenues 843,920 662,037 536,539
Total Segments | Operating Segments | Inter-Segment      
Segment Information [Line Items]      
Revenues € 70,113 € 57,423 € 46,506